Our Team

We are a team of talented scientists and industry veterans who have deep experience 
in bringing therapies from discovery, through development, and ultimately to the 
patients who need them. Our company believes that we can make an impact through 
scientific rigor, compassion for one another and unwavering tenacity. 

John Quisel, JD, PhD
Chief Executive Officer
Maria Beconi, PhD
SVP, Translational R&D
Srikanth Venkatraman, PhD
SVP, Head of Chemistry
Joanne Bryce, CPA
Chief Financial Officer
Jonathan Yu
SVP, Corporate Development
Will Savage, MD, PhD
VP, Clinical Development
Donald Nicholson, PhD
Executive Chairman
Kevin Bitterman, PhD
Partner, Atlas Venture
Nilesh Kumar, PhD, MBA
Novo Ventures
Brian MacDonald, MB, ChB, PhD
Founder and Senior Advisor
John Quisel, JD, PhD
Chief Executive Officer
Liam Ratcliffe, MD, PhD
Access Biotechnology
William White, MPP, JD
Akero Therapeutics
Mark Fleming, MD, DPhil
Pathologist-in-Chief, Department of Pathology, Professor of Pathology, Harvard Medical School
Tomas Ganz, MD, PhD
Distinguished Professor of Medicine and Pathology, David Geffen School of Medicine, UCLA
Elizabeta Nemeth, PhD
Professor of Medicine, David Geffen School of Medicine, UCLA
Stefano Rivella, PhD
Professor of Pediatrics and Chair of Pediatric Hematology Children’s Hospital of Philadelphia
Uma Sinha, PhD
CSO at BridgeBio Pharma, Former CSO at Global Blood Therapeutics
Srdan Verstovsek, MD, PhD
Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center